Pharmacovigilance [Pharmacovigilance update].


Autoria(s): Fogarasi Szabo N.; Diezi L.; Delenclos L.; Renard D.; Chtioui H.; Rothuizen L.E.; Buclin T.; Livio F.
Data(s)

01/01/2015

Resumo

The main pharmacovigilance updates in 2014 are reviewed. Ivabradine: increased risk of cardiovascular death and myocardial infarction in patients with symptomatic angina treated with high dosages. Clopidogrel: rare observations of acquired hemophilia. Orlistat: may reduce the absorption of HIV antiretrovirals. Ponatinib: increased risk of arteriopathy and thrombosis. Axitinib: significant risk of heart failure (class effect). Tocilizumab: possible causal relationship with the emergence or aggravation of psoriasis. Lithium: hypercalcemia and hyperparathyroidism commonly observed. Sildenalfil: suspected causal association with melanoma, so far not proven, Methylphenidate: rare observations of priapism. St John's wort (Hypericum): reduced effectiveness of hormonal contraceptives, including implants.

Identificador

http://serval.unil.ch/?id=serval:BIB_D8A2874AB9AF

isbn:1660-9379 (Print)

pmid:25799668

http://my.unil.ch/serval/document/BIB_D8A2874AB9AF.pdf

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_D8A2874AB9AF8

Idioma(s)

fr

Direitos

Restricted: indefinite embargo

info:eu-repo/semantics/restrictedAccess

Fonte

Revue Médicale Suisse, vol. 11, no. 456-457, pp. 124-128

Palavras-Chave #Humans; Pharmacovigilance
Tipo

info:eu-repo/semantics/review

article